The global next-generation antibody therapeutics market was worth $1,490.0 million in 2014, and it is expected to grow at a CAGR of 20.9% during 2015-2020. Oncology based next-generation antibody therapeutics dominated the global market in 2014. Whereas, on the basis of technology, the antibody-drug conjugates (ADCs) accounted for the highest share in the global next-generation antibody therapeutics market in the same year. The next-generation antibody therapeutics market is escalating with high growth rate due to several favorable macro-economic factors, including increased R&D activities. In addition, increasing incidence of chronic diseases is also driving the next-generation antibody therapeutics market at a significant rate. Next-generation antibody therapeutics is more advantageous as compared to traditional antibodies. Moreover, treatment using next-generation antibody therapeutics has lesser side effects as compared to other treatment options; as a result, the market for next-generation antibody therapeutics is expected to boost in near future.
Browse Here For Full Report:
http://www.acutemarketreports.com/report/next-generation-antibody-market
Advancements in antibody technology have helped in the development of next-generation antibody therapeutics, such as ADCs and BsAbs, with improved features. Technological advancements in antibody therapeutics have been imparting positive impact on next-generation antibody therapeutics market, as people are increasingly adopting next-generation antibody therapeutics for getting efficient treatment. Next-generation antibody therapeutics market in developing economies, such as Asia-Pacific, Africa, and Latin America, have been growing at a significant pace due to rising economic active population, which is increasing people’s buying power; and increasing awareness for getting effective treatment.
Government initiatives to provide complete healthcare with improved healthcare facilities are increasing the demand for advanced treatment options. Increasing healthcare expenditure makes next-generation antibody therapeutics reasonably priced, and hence, raising its adoption rate. Rising global gross domestic product (GDP) and increasing healthcare expenditure in various countries have a positive impact on growth of the next-generation antibody therapeutics market.
Browse All Reports of This Category http://www.acutemarketreports.com/category/healthcare-market
As a result of high potential of ADC technology, healthcare providers are specifically using ADC technology for the development of next-generation antibody therapeutics for the treatment of cancer. ADCs help in providing targeted therapy with minimum side effects in patients with cancer. The ADCs market, which increased at a CAGR of approximately 87.2% during 2011-2014, also boosted the market for next-generation antibody therapeutics during the period.
Sample Request : http://www.acutemarketreports.com/request-free-sample/39744
The restraints associated with next-generation antibody therapeutics market include high cost of next-generation antibody therapeutics and strict regulatory requirements and long approval time for new drug. Drug development is a complex process and involves various risk factors. Drug approval requires passing through a regulation process that is rigorous and time-consuming. Hence, strict regulatory requirements and extended approval time for new drugs have a negative impact on the growth of the next-generation antibody therapeutics market. In addition, high cost of next-generation therapeutics decreases its popularity among healthcare providers and patients, thus limiting its use. Healthcare organizations and researchers are focusing on a cost-effective manufacturing process to produce next-generation antibody therapeutics.
The key companies operating in the global next-generation antibody therapeutics market include Kyowa Hakko Kirin Co., Ltd., Dyax Corp., AstraZeneca plc, F.Hoffmann-La Roche Ltd, Bayer AG, Pfizer, Inc., Seattle Genetics, Inc., Bristol-Myers Squibb Company, Takeda Pharmaceuticals Company Limited, and Biogen.
About Us :
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products,establishments and trends. Our database consists of 200,000+ market research report s with detailed & minute market research.
Contact:
Chris Paul
Office No 01, 1st Floor,
Aditi Mall, Baner, Pune,
MH, 411045 India
Phone: 1-855-455-8662
Toll Free: 1-855-455-8662
Email: sales@acutemarketreports.com
Website: www.acutemarketreports.com/
Browse Here For Full Report:
http://www.acutemarketreports.com/report/next-generation-antibody-market
Advancements in antibody technology have helped in the development of next-generation antibody therapeutics, such as ADCs and BsAbs, with improved features. Technological advancements in antibody therapeutics have been imparting positive impact on next-generation antibody therapeutics market, as people are increasingly adopting next-generation antibody therapeutics for getting efficient treatment. Next-generation antibody therapeutics market in developing economies, such as Asia-Pacific, Africa, and Latin America, have been growing at a significant pace due to rising economic active population, which is increasing people’s buying power; and increasing awareness for getting effective treatment.
Government initiatives to provide complete healthcare with improved healthcare facilities are increasing the demand for advanced treatment options. Increasing healthcare expenditure makes next-generation antibody therapeutics reasonably priced, and hence, raising its adoption rate. Rising global gross domestic product (GDP) and increasing healthcare expenditure in various countries have a positive impact on growth of the next-generation antibody therapeutics market.
Browse All Reports of This Category http://www.acutemarketreports.com/category/healthcare-market
As a result of high potential of ADC technology, healthcare providers are specifically using ADC technology for the development of next-generation antibody therapeutics for the treatment of cancer. ADCs help in providing targeted therapy with minimum side effects in patients with cancer. The ADCs market, which increased at a CAGR of approximately 87.2% during 2011-2014, also boosted the market for next-generation antibody therapeutics during the period.
Sample Request : http://www.acutemarketreports.com/request-free-sample/39744
The restraints associated with next-generation antibody therapeutics market include high cost of next-generation antibody therapeutics and strict regulatory requirements and long approval time for new drug. Drug development is a complex process and involves various risk factors. Drug approval requires passing through a regulation process that is rigorous and time-consuming. Hence, strict regulatory requirements and extended approval time for new drugs have a negative impact on the growth of the next-generation antibody therapeutics market. In addition, high cost of next-generation therapeutics decreases its popularity among healthcare providers and patients, thus limiting its use. Healthcare organizations and researchers are focusing on a cost-effective manufacturing process to produce next-generation antibody therapeutics.
The key companies operating in the global next-generation antibody therapeutics market include Kyowa Hakko Kirin Co., Ltd., Dyax Corp., AstraZeneca plc, F.Hoffmann-La Roche Ltd, Bayer AG, Pfizer, Inc., Seattle Genetics, Inc., Bristol-Myers Squibb Company, Takeda Pharmaceuticals Company Limited, and Biogen.
About Us :
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products,establishments and trends. Our database consists of 200,000+ market research report s with detailed & minute market research.
Contact:
Chris Paul
Office No 01, 1st Floor,
Aditi Mall, Baner, Pune,
MH, 411045 India
Phone: 1-855-455-8662
Toll Free: 1-855-455-8662
Email: sales@acutemarketreports.com
Website: www.acutemarketreports.com/
No comments:
Post a Comment